A logistic regression model for 289 cases of schizophrenic offenders in a Swiss forensic hospital between 1995 and 2016 revealed the following factors for above average levels of antipsychotic overdosing and polypharmacy: Odds for overdosing increased in absence of a personality disorder (237%), for each point increase in emotional withdrawal (63.5%) and motor retardation (71.7%), and decreased for poor rapport (42.3%) recorded at admission. Odds for polypharmacy increased with complaints about physicians (157%), for each point increase in IQ (3.6%; range = 65–131, M = 92, SD = 14), reduction of the security level of the ward (36.8%; four levels), and for each point increase in poor attention (27.6%) at admission. It decreased with each previous conviction (10.9%; range = 1–21, M = 3, SD = 2), breaking of rules (46.4%) and the administration of compulsory measures (55.7%) on the ward, a poor legal prognosis (29.4%, four levels), and each point increase in grandiosity (40.3%), passive social withdrawal (42.3%), and depressive symptoms (38.7%) at admission.
ArlotS.CelisseA. (2010). A survey of cross-validation procedures for model selection. Statistics Surveys, 4, 40–79. https://doi.org/10.1214/09-SS054
2.
BarbuiC.NosèM.MazziM. A.ThornicroftG.ScheneA.BeckerT.. . . KoeterM. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21(6), 355–362. https://doi.org/10.1097/01.yic.0000224785.68040.43
BarnesT. R.Shingleton-SmithA.PatonC. (2009). Antipsychotic long-acting injections: Prescribing practice in the UK. The British Journal of Psychiatry, 195(S52), s37–s42.
5.
BrennanP. F.HaysB. J. (1992). Focus on psychometrics the kappa statistic for establishing interrater reliability in the secondary analysis of qualitative clinical data. Research in Nursing & Health, 15(2), 153–158. https://doi.org/10.1002/nur.4770150210
6.
CarpenterW. T.Jr.HeinrichsD. W.AlphsL. D. (1985). Treatment of negative symptoms. Schizophrenia Bulletin, 11(3), 440–452. https://doi.org/10.1093/schbul/11.3.440
7.
ConnollyA.TaylorD. (2014). Factors associated with non evidence-based prescribing of antipsychotics. Therapeutic Advances in Psychopharmacology, 4(6), 247–256. https://doi.org/10.1177/2045125314540298
8.
CorrellC. U.FredericksonA. M.KaneJ. M.ManuP. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 89(1-3), 91–100.
9.
ElieD.PoirierM.ChianettaJ.DurandM.GrégoireC.GrignonS. (2010). Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology, 24(7), 1037–1044.
10.
GardnerD. M.MurphyA. L.O’DonnellH.CentorrinoF.BaldessariniR. J. (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry, 167(6), 686–693. https://doi.org/10.1176/appi.ajp.2009.09060802
11.
GrechP.TaylorD. (2012). Long-term antipsychotic polypharmacy: How does it start, why does it continue?Therapeutic Advances in Psychopharmacology, 2(1), 5–11.
12.
HarringtonM.LelliottP.PatonC.OkochaC.DuffettR.SenskyT. (2002). The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin, 26(11), 414–418. https://doi.org/10.1192/pb.26.11.414
13.
HawC.StubbsJ. (2003). Prescribing errors at a psychiatric hospital. Pharmacy in Practice, 13(2), 64–66.
14.
HeinzeG.WallischC.DunklerD. (2018). Variable selection–a review and recommendations for the practicing statistician. Biometrical Journal, 60(3), 431–449. https://doi.org/10.1002/bimj.201700067
15.
HettigeN. C.KennedyJ. L.De LucaV. (2014). Does a history of suicide attempt predict higher antipsychotic dosage in schizophrenia?Psychopharmacology, 231(12), 2507–2513.
16.
HsiehH.-F.ShannonS. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288. https://doi.org/10.1177/1049732305276687
17.
JoukamaaM.HeliövaaraM.KnektP.AromaaA.RaitasaloR.LehtinenV. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry, 188(2), 122–127.
18.
KasckowJ.FelmetK.ZisookS. (2011). Managing suicide risk in patients with schizophrenia. CNS Drugs, 25(2), 129–143.
19.
KayS. R.FiszbeinA.OpferL. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.
20.
KohaviR. (1995). A study of cross-validation and bootstrap for accuracy estimation and model selection [Paper presentation]. International Joint Conferences on Artificial Intelligence, Los Altos, CA, United States.
21.
KongM.RaiS. N.BolliR. (2014). Statistical methods for selecting maximum effective dose and evaluating treatment effect when dose–response is monotonic. Statistics in Biopharmaceutical Research, 6(1), 16–29. https://doi.org/10.1080/19466315.2013.826596
22.
LambertM. J.BerginA. (1993). Handbook of psychotherapy and behavior change. John Wiley.
23.
LelliottP.PatonC.HarringtonM.KonsolakiM.SenskyT.OkochaC. (2002). The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26(11), 411–414.
24.
LeuchtS.SamaraM.HeresS.DavisJ. M. (2016). Dose equivalents for antipsychotic drugs: The DDD method. Schizophrenia Bulletin, 42(Suppl_1), S90–S94. https://doi.org/10.1093/schbul/sbv167
25.
LeuchtS.SamaraM.HeresS.PatelM. X.FurukawaT.CiprianiA.. . . DavisJ. M. (2015). Dose equivalents for second-generation antipsychotic drugs: The classical mean dose method. Schizophrenia Bulletin, 41(6), 1397–1402. https://doi.org/10.1093/schbul/sbv037
26.
LeuchtS.SamaraM.HeresS.PatelM. X.WoodsS. W.DavisJ. M. (2014). Dose equivalents for second-generation antipsychotics: The minimum effective dose method. Schizophrenia Bulletin, 40(2), 314–326. https://doi.org/10.1093/schbul/sbu001
27.
MaceS.TaylorD. (2015). Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: Results of a 6-year quality improvement programme. Therapeutic Advances in Psychopharmacology, 5(1), 4–12.
28.
MargetićB.MargetićB. A.IvanecD.PalijanT. Ž. (2017). What leads to high antipsychotic dosing in forensic patients with schizophrenia?CNS Spectrums, 22(6), 435–438. https://doi.org/10.1017/S1092852916000675
29.
MorrissetteD. A.StahlS. M. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums, 19(5), 439–448. https://doi.org/10.1017/S1092852914000388
30.
National Institute for Health and Clinical Excellance. (2014). Psychosis and schizophrenia in adults: Prevention and management. NICE clinical guideline CG178.
31.
NosèM.BarbuiC. (2008). A simple approach to manage dosages in drug-epidemiology research. Epidemiology and Psychiatric Sciences, 17(3), 186–187. https://doi.org/10.1017/S1121189X00001263
32.
ReyM.-J.SchulzP.CostaC.DickP.TissotR. (1989). Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology, 4(2), 95–104.
33.
RijckenC. A.MonsterT. B.BrouwersJ. R. (2003). Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?Journal of Clinical Psychopharmacology, 23(6), 657–659.
34.
RoffmanJ. L.LambertiJ. S.AchtyesE.MacklinE. A.GalendezG. C.RaekeL. H.. . . GoffD. C. (2013). Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry, 70(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2013.900
35.
Royal College of Psychiatrists. (2014). Consensus statement on high-dose antipsychotic medication.
36.
SinghS. P.SinghV.KarN.ChanK. (2010). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. The British Journal of Psychiatry, 197(3), 174–179.
37.
StahlS. M.MorrissetteD. A.CitromeL.SakladS. R.CummingsM. A.MeyerJ. M.. . .WarburtonK. D. (2013). “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectrums, 18(3), 150–162. https://doi.org/10.1017/S109285291300014X
38.
StahlS. M.MorrissetteD. A.CummingsM.AzizianA.BaderS.BroderickC.. . . O’DayJ. (2014). California state hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectrums, 19(5), 449–465. https://doi.org/10.1017/S1092852914000376
39.
Stone-BrownK.NajiM.FrancioniA.MyersK.SamarendraH.Mushtaq-ChaudhryH.. . . LarkinF. (2016). Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. CNS Spectrums, 21(1), 60–69. https://doi.org/10.1017/S1092852915000784
40.
SweilehW. M.OdehJ. B.ShraimN. Y.Sa’edH. Z.SawalhaA. F.Al-JabiS. W. (2014). Evaluation of defined daily dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharmaceutical Journal, 22(2), 127–132. https://doi.org/10.1016/j.jsps.2013.03.003
41.
TaiminenT. J.KujariH. (1994). Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. Acta Psychiatrica Scandinavica, 90(4), 247–251.
42.
TaylorD. M.BarnesT. R.YoungA. H. (2018). The Maudsley prescribing guidelines in psychiatry. John Wiley.
43.
TaylorD. M.SmithL. (2009). Augmentation of clozapine with a second antipsychotic—A meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica, 119(6), 419–425.
Van der BorghtK.Van CraenenbroeckE.LecocqP.Van HoutteM.Van KerckhoveB.BachelerL.. . . van VlijmenH. (2011). Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations. BMC Bioinformatics, 12(1), Article 386. https://doi.org/10.1186/1471-2105-12-386
46.
WoodsS. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry, 4(6), 663–667.
47.
YamashitaT.YamashitaK.KamimuraR. (2007). A stepwise AIC method for variable selection in linear regression. Communications in Statistics—Theory and Methods, 36(13), 2395–2403. https://doi.org/10.1080/03610920701215639
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
